View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Chemours Co: 1 director

A director at Chemours Co bought 10,200 shares at 19.262USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

Moody's Ratings assigns B1 rating to Chemours new unsecured notes; out...

Moody's Ratings (Moody's) assigned a B1 rating to The Chemours Company's ("Chemours") new senior unsecured notes due 2033. Proceeds from the notes will be used for general corporate purposes including the redemption of €441 million of senior unsecured notes maturing in May 2026. The outlook is stabl...

Chemours Company, (The): Update after conclusion of ratings review

Our credit view reflects Chemours' leading TiO2 market position, advantaged TiO2 cost position and expected growth in the TSS business over time, but tempered by potential PFAS liabilities.

Moody's Ratings confirms Chemours' Ba3 CFR and other debt ratings; out...

Moody's Ratings (Moody's) confirmed The Chemours Company's ("Chemours") Ba3 Corporate Family Rating ("CFR"), Ba3-PD Probability of Default Rating ("PDR"), Ba1 rating on its senior secured bank credit facilities, and the B1 rating on its senior unsecured notes. The speculative grade liquidity rating ...

Moody's places Chemours' ratings under review for downgrade

Moody's Investors Service (Moody's) has placed under review for downgrade The Chemours Company's ("Chemours") Ba3 corporate family rating ("CFR"), Ba3-PD probability of default rating ("PDR"), Ba1 rating on its senior secured credit facilities, and the B1 rating on its senior unsecured notes. Previo...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Chemours Company, (The): Update to credit analysis

Our credit view reflects weakening metrics and a difficult macroeconomic environment as well as significant environmental liabilities related to PFAS.

Valens Research
  • Valens Research

CC - Valens Credit Report - 2023 11 20

Credit markets are grossly overstating CC's credit risk with a YTW of 9.084% relative to an Intrinsic YTW of 6.454%, while CDS markets are materially overstating credit risk with a CDS of 355bps relative to an Intrinsic CDS of 180bps. Furthermore, Moody's is overstating the company's fundamental credit risk, with its speculative Ba3 credit rating three notches lower than Valens' XO (Baa3) credit rating. Incentives Dictate Behavior™ analysis highlights mostly positive signals for creditors. CC's...

Valens Research
  • Valens Research

Valens Credit Weekly Insights - 2023 08 16

Valens Credit Research team highlights CC, which has a compelling bond offering that we believe the market is currently mispricing, with strong fundamentals, favorable management alignment, and an actionable trade.

Valens Research
  • Valens Research

CC - Valens Credit Report - 2023 08 14

Credit markets are materially overstating CC's credit risk with a YTW of 7.737% relative to an Intrinsic YTW of 5.716%, while CDS markets are overstating credit risk with a CDS of 255bps relative to an Intrinsic CDS of 157bps. Furthermore, Moody's is overstating the company's fundamental credit risk, with it speculative Ba3 credit rating three notches lower than Valens' XO (Baa3) credit rating. Incentives Dictate Behavior™ analysis highlights mostly positive signals for creditors. CC's compensa...

Moody's assigns Ba1 to Chemours' term loans; outlook stable

Moody's Investors Service (Moody's) has assigned a Ba1 rating to The Chemours Company's ("Chemours") upsized and amended and extended $960 million Senior Secured Term Loan B3 due 2028 and €515 million Senior Secured Term Loan B3 due 2028. Proceeds from the issuance will be used to repay Chemours' ex...

The Chemours Company - March 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Valens Research
  • Valens Research

CC - Valens Credit Report - 2023 05 09

Credit markets are grossly overstating CC's credit risk with a YTW of 8.024% relative to an Intrinsic YTW of 5.184%, while CDS markets are materially overstating credit risk with a CDS of 363bps relative to an Intrinsic CDS of 172bps. Furthermore, Moody's is overstating the company's fundamental credit risk, with it speculative Ba3 credit rating three notches lower than Valens' XO (Baa3) credit rating. Incentive Dictate Behavior™ analysis highlights mostly positive signals for creditors. CC's c...

The Chemours Company - December 2022 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Valens Research
  • Valens Research

CC - Valens Credit Report - 2023 03 06

Credit markets are grossly overstating CC's credit risk with a YTW of 8.420% relative to an Intrinsic YTW of 5.720%, while CDS markets are materially overstating credit risk with a CDS of 389bps relative to an Intrinsic CDS of 156bps. Furthermore, Moody's is overstating the company's fundamental credit risk, with it speculative Ba3 credit rating three notches lower than Valens' XO (Baa3) credit rating. Incentive Dictate Behavior™ analysis highlights mostly positive signals for creditors. CC's c...

Valens Research
  • Valens Research

Valens Credit Weekly Insights - 2022 12 14

Valens Credit Research team highlights CC, which has a compelling bond offering that we believe the market is currently mispricing, with strong fundamentals, favorable management alignment, and an actionable trade.

Valens Research
  • Valens Research

CC - Valens Credit Report - 2022 11 30

Credit markets are grossly overstating CC's credit risk with a YTW of 7.749% and a CDS of 379bps, relative to an Intrinsic YTW of 4.320% and an Intrinsic CDS of 154bps. Furthermore, Moody's is materially overstating the company's fundamental credit risk, with its speculative Ba3 credit rating five notches lower than Valens' IG4+ (Baa1) credit rating. Incentive Dictate Behavior™ analysis highlights mostly positive signals for creditors. CC's compensation framework incentivizes management to impr...

The Chemours Company - September 2022 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Chemours Company, (The): Update to credit analysis

Updated credit analysis after the move to a stable outlook reflects the company's substantial size and strong credit metrics offset by potential PFAS litigation liabilities.

Moody's changes Chemours outlook to stable

Moody's Investors Service ("Moody's") affirmed the existing ratings of The Chemours Company ("Chemours"), including its Ba3 corporate family rating ("CFR"), Ba1 rating on its senior secured credit facilities, and the B1 rating on its senior unsecured notes. Moody's also changed Chemours' outlook to ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch